Related Experiment Video
Updated: Oct 16, 2025
12:57
X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022
2.5K
Molecular Pathways in Prolactinomas: Translational and Therapeutic Implications
Betina Biagetti1, Rafael Simò1
1Diabetes and Metabolism Research Unit, Vall d'Hebron University Hospital and Vall d'Hebron Research Institute (VHIR), Universidad Autónoma de Barcelona, 08035 Barcelona, Spain.
International Journal of Molecular Sciences
|October 23, 2021
Summary
Prolactinomas, often benign pituitary tumors, can be aggressive. Understanding their molecular pathways is key to identifying aggressive subtypes and personalizing treatment for better patient outcomes.
Area of Science:
- Endocrinology
- Oncology
- Molecular Biology
Background:
- Prolactinomas are the most common functional pituitary tumors.
- While typically benign, a subset exhibits aggressive behavior with poor prognostic indicators.
- Tumor heterogeneity necessitates a deeper understanding of underlying molecular mechanisms.
Purpose of the Study:
- To provide an overview of molecular pathways implicated in prolactinoma behavior.
- To enhance understanding of prolactinoma development and management strategies.
- To facilitate the identification of aggressive prolactinomas and guide personalized therapeutics.
Main Methods:
- Literature review of molecular pathways in prolactinoma.
- Analysis of clinical, radiological, and pathological features associated with prognosis.
- Synthesis of current knowledge on tumor development and behavior.
Main Results:
- Prolactinomas display significant heterogeneity.
- Specific molecular pathways are linked to aggressive tumor behavior.
- Current understanding allows for preliminary identification of prognostic factors.
Conclusions:
- Understanding prolactinoma molecular pathways is crucial for improved diagnosis and management.
- Personalized therapeutic strategies can be developed based on molecular profiles.
- Further research into molecular mechanisms will refine treatment approaches for aggressive prolactinomas.
Related Concept Videos
02:57Targeted Cancer Therapies
7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.9K
01:19Interactions Between Signaling Pathways
6.6K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.6K
03:03mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
02:23Abnormal Proliferation
4.7K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.7K
01:22PI3K/mTOR/AKT Signaling Pathway
4.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.2K
02:07Tumor Progression
6.6K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.6K